Sangamo Therapeutics, Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
 |
return to message board, top of board |
Re: Sanofi says ST400(**)(4) Proof of concept study read-out in Beta thalassemia H1 2021 BIVV003(**)(4) Proof of concept study read-out in Sickle Cell Disease H1 2021"I wonder about the fact that both are at the bottom of the list" C'mon - the fact that those programs are at the very bottom of the list is clearly a secret tell to the investment community that the data are looking AMAZING and that a buyout is imminent! Back up the truck!!! Beep! Beep! Beep!
|
||||||||||||||||||
|
|
return to message board, top of board |
